



DEVELOPMENT AND VALIDATION OF STABILITY INDICATING RP-HPLC METHOD FOR 
SIMULTANEOUS DETERMINATION OF ASPIRIN, ROSUVASTATIN, CLOPIDOGREL IN BULK 
AND PHARMACEUTICAL DOSAGE FORM 
Original Article 
 
POOJA PISAL, GANESH NIGADE, AMOL KALE, SMITA PAWAR




Received: 06 Jul 2018 Revised and Accepted: 01 Sep 2018 
ABSTRACT 
Objective: To develop a novel, accurate, precise and linear reverse phase high-performance liquid chromatography (RP-HPLC) and Stability 
Indicating Assay Method (SIAMs) for simultaneous, qualitative and quantitative estimation of aspirin, rosuvastatin and clopidogrel in bulk and 
pharmaceutical dosage form as per International Conference on Harmonization (ICH) guidelines. 
Method: In the present work, good chromatographic separation was achieved by isocratic method using a BISCOF HPLC C18 
Results: The retention time of aspirin, rosuvastatin, and clopidogrel was found to be 4.3 min, 7.6 min and 16.6 min respectively. For linearity seven-
point calibration curves were obtained in a concentration range from 1-7 µg/ml for aspirin, rosuvastatin and clopidogrel with correlation coefficient 
0.999, 0.9989, 0.9988 respectively. The high recovery values (99%-101%) indicate a satisfactory accuracy. The low percent relative standard 
deviation (% RSD) values in the precision study reveal that the method is precise. In the present study stability indicating an RP-HPLC method for 
the combination was tested by degrading the drugs together under various stress condition like acid, base and neutral hydrolysis, oxidation, thermal 
and photolytic stress which is recommended by ICH. 
column (250 mm ×4.6, 
5 µm) and a mobile phase consisting of water at pH 2.51 with 0.1 % (v/v) orthophosphoric acid (OPA): acetonitrile in the ratio 50:50, at a flow rate 
of 1 ml/min. The effluents obtained were monitored at 237 nm with the UV-visible detector. 
Conclusion: The developed RP-HPLC method is simple, economic, specific, accurate and precise for the simultaneous estimation of aspirin, 
rosuvastatin, and clopidogrel in the combined capsule dosage form. The developed stability indicating analytical method can be used to check the 
stability of the compounds and was found suitable to determine % degradation of drugs in pharmaceutical dosage form. 
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Platelet aggregation and thrombus formation play a critical role in 
the initiation and development of key complications of acute 
coronary syndromes (ACSs). HMG-CoA Reductase catalyzes the 
conversion of HMG-CoA to mevalonic acid, the rate-limiting step in 
cholesterol biosynthesis and it is used to reduce plasma cholesterol 
levels and prevent cardiovascular disease (CVD), antiplatelet 
therapy and antithrombotic therapy have been demonstrated to 
modify clinical outcome favorably, and recent trials of 
revascularization in ACSs have demonstrated a reduction in the 
frequency of major cardiac events [1-3]. Yet, all effective 
antithrombotic agents also increase the risk of bleeding. Especially 
bleeding that results from vascular accessories associated with 
surgery, including coronary artery bypass grafting (CABG) [4-6]. 
Aspirin is chemically acetylsalicylic acid. Aspirin is a non-steroidal 
anti-inflammatory drug that exhibits anti-inflammatory, analgesic 
and antipyretic activities. Rosuvastatin calcium, chemically it is 7-[4-
(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-
ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate. It is used as 
antilipidemic. Clopidogrel bisulfate, chemically it is [S-(a)(2-
chlorophenyl)-6,7-dihydrothieno (3,2-C) pyridine-5 (4H) acetic acid 
methyl ester sulfate]. It is an antithrombotic agents. 
The combination of aspirin, rosuvastatin, clopidogrel is available in 
the market as a capsule and tablet dosage form and is choice of drug 
for treatment of heart attack prevention. Rosumac gold 
manufactured by Macleod pharmaceuticals was used for RP-HPLC 
study. The strengths of the drug in the capsule chosen are aspirin 75 
mg, rosuvastatin 10 mg, and clopidogrel 75 mg. 
The literature survey revealed that no method has been reported for 
estimation of aspirin, rosuvastatin, and clopidogrel using RP-HPLC. 
UV spectrophotometric methods have been reported for estimation 
of aspirin, rosuvastatin and clopidogrel in the pure form [7]. Some 
methods have been reported for stability indicating assay method 
for simultaneous estimation of aspirin and rosuvastatin [8, 9] and 
aspirin and clopidogrel in combined dosage form [10]. The 
clopidogrel bisulphate was analysed using bioanalytical RP-HPLC 
method [11]. Also, simultaneous estimation of clopidogrel and 
atorvastatin was carried out using bioanalytical UFLC method [12]. 
However, no RP-HPLC method is available for simultaneous 
determination of aspirin, rosuvastatin and clopidogrel and its 
pharmaceutical dosage form. Similarly, no studies have been carried 
out on Stability Indicating Assay Methods for simultaneous 
determination of aspirin, rosuvastatin and clopidogrel in bulk drugs 
and pharmaceutical dosage form.  
In the present study, stability indicating an RP-HPLC method for the 
combination was tested by degrading the drugs together under 
various stress conditions like acid hydrolysis, base hydrolysis, and 
oxidation, thermal and photolytic stress as per ICH guideline. 
MATERIALS AND METHODS  
Aspirin, rosuvastatin and clopidogrel pure compounds were 
supplied by Research-lab fine chem. Industries, Mumbai, Lupin Ltd., 
Pune, Cadila Healthcare Ltd, Goa. Rosumac gold capsule 
manufactured by Macleod Pharmaceuticals, Mumbai, containing the 
labeled amount of 75 mg aspirin, 10 mg rosuvastatin, and 75 mg 
Clopidogrel was purchased from local markets. All the chemicals 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491              Vol 10, Issue 10, 2018 
Pawar et al. 
Int J Pharm Pharm Sci, Vol 10, Issue 10, 51-56 
51 
used were of analytical grade. HPLC grade water and solvents were 
used to prepare all the solutions. 
HPLC instrumentation and chromatographic conditions 
The chromatographic system used to perform analytical method 
development and validation of this assay method was comprised of 
(SHIMADZU, HPLC) with LC-20 AD pump, with software LC software 
and UV-Visible detector SPD-20A. Chromatographic analysis was 
performed on a BISCOF C18
Standard stock solution (1000 µg/ml) of aspirin, rosuvastatin, and 
clopidogrel was prepared in optimized mobile phase. Accurately 
weighted 100 mg of each drug is transferred to 100 ml volumetric 
flask and dissolved in the selected mobile phase. It was then 
sonicated for 20 min. The solution was diluted up to volume with the 
same mobile phase. In order to the obtained test solution, stock 
solutions were further diluted to make 1 µg/ml. 
 (250 mm 4.6 mm ID, 5 μm particle size) 
column. The mobile phase consisted of water at pH 2.51 with 0.1 % 
(v/v) orthophosphoric acid (v/v): acetonitrile (50:50). The flow rate 
of the mobile phase was adjusted to 1.0 ml/min, and the injection 
volume was 20 μl. Detection was performed at 237 nm. Isocratic 
analytical method was used. 
Preparation of stock solution 
In the present work, an analytical method based on LC using UV 
detection was developed and validated for the determination of 
aspirin, rosuvastatin, and clopidogrel in a capsule formulation. The 
analytical conditions were selected, keeping in mind the different 
chemical nature of aspirin, rosuvastatin, and clopidogrel. The 
development trials were taken by using the degraded sample of each 
component was done, by keeping them in various extreme 
conditions. 
The column selection has been done on the basis of backpressure, 
resolution, peak shape, theoretical plates and day-to-day 
reproducibility of the retention time and resolution between aspirin, 
rosuvastatin and clopidogrel peak. After evaluating all these factors, 
C18 
 
250 mm, 4.6 mm ID, 5 μm particle size) column was found to be 
giving satisfactory results. 
 
Fig. 1: Chromatogram of aspirin, rosuvastatin, and clopidogrel 
 
Forced degradation studies 
Table 1: Forced degradation condition 
Degradation condition 
Acidic  1 h refluxed with 0.1 N HCl for 80 °C. 
Basic 1 h refluxed with 0.1 N NaOH for 80 °C. 
Neutral  1 h kept at room temperature. 
Oxidation  1 h refluxed with 6 % v/v H2O
Thermal  
2. 
24 h kept in a dry oven at 105 °C. 
Photolytic  UV light-254 nm for 5 h. 
 
 
Fig. 2: Degradation of the sample by acidic conditions (A1-First degradants of aspirin, R1-First degradant of rosuvastatin, R2-Second 
degradant of rosuvastatin, C1-First degradant of clopidogrel) 
 
 
Fig. 3: Degradation of sample by alkaline condition (A1-First degradant of aspirin, R1-First degradant of rosuvastatin, C1-First degradant 
of clopidogrel) 
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Fig. 4: Degradation of the sample by neutral condition (A1-First degradants of aspirin, R1-First degradant of rosuvastatin, R2-Second 
degradant of rosuvastatin, C1-First degradant of clopidogrel, C2-second degradant of clopidogrel) 
 
 
Fig. 5: Degradation of the sample by Oxidative condition (A1-First degradants of aspirin, R1-first degradant of rosuvastatin, R2-Second 
degradant of rosuvastatin, C1-first degradant of clopidogrel) 
 
 
Fig. 6: Degradation of the sample by thermal condition (A1-first degradants of aspirin, R1-first degradant of rosuvastatin, R2-Second 
degradant of rosuvastatin, C1-First degradant of clopidogrel, C2-Second degradant of clopidogrel) 
 
 
Fig. 7: Degradation of the sample by photolysis condition (R1-first degradant of rosuvastatin, R2-second degradant of rosuvastatin, C1-
first degradant of clopidogrel, C2-second degradant of clopidogrel) 
 
RESULTS AND DISCUSSION 
The retention time of all three drugs, aspirin, rosuvastatin, and 
clopidogrel decreased as the pH of the mobile phase increased. This 
may be due to the ionized state of the drugs. The satisfactory 
retention time was achieved for the selected drug at 2.51. Various 
combinations of solvents were tried to get satisfactory retention 
time and proper resolution of peaks. The C18 
At 50:50 % ratio of acetonitrile: water at pH 2.51 adjusted to 0.1 % 
(v/v) OPA a symmetrical peak eluted at around 3.9 min, 7.5 min and 
16.9 min with good capacity and it was selected for further studies. 
column was used which 
is hydrophobic in nature. The column was selected as it resulted in 
proper resolution of all three drugs without tailing. 
1 ml/min flow rate gave symmetrical peak with the acceptable 
capacity factor. For the present study, 1 ml/min was selected on the 
basis of less retention time, good peak shape, the acceptable back 
pressure of aspirin, rosuvastatin calcium and clopidogrel. At a flow 
rate of 0.8 ml/min peak broadening was observed, and peak shape 
was irregular. 
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Method development 
A reverse phase HPLC method with stability indicating assay 
methods was developed keeping in mind the system suitability 
parameter that is a resolution factor between peaks, tailing factor, 
the number of theoretical plates, run time. The developed optimized 
method resulted in elution of aspirin at 4.3 min, rosuvastatin at 7.6 
min and clopidogrel at 16.6 min. in fig. 1 represent chromatogram of 
all three drugs. System suitability tests are an integral part of 
method development and are used to ensure adequate performance 
of the chromatography system. Retention time, the number of 
theoretical plates, peak resolution and peak tailing factor were 
evaluated for seven replicate injections of the standard working 
concentration. The results given in table 2 were within the 
acceptable limits. 
 
Table 2: Results of system suitability studies 
Parameters  Aspirin Rosuvastatin Clopidogrel 
Retention time (min) 4.3 7.6 16.6 
Tailing factor 1.1 1.0 0.909 
Capacity factor 1.052 2.354 1.3 
Theoretical plate  10313 12884 16149 
Resolution factor  4.1 5.10 2.10 
 
Method validation 
Validation of the analytical method is the process that establishes by 
laboratory studies in which the performance characteristics of the 
method meets the requirements for the intended analytical 
application [13-14]. The developed HPLC method was validated 
according to ICH guideline for validation of analytical procedures. 
The method was validated for the parameters like linearity, 
accuracy, system precision, method precision, robustness, limit of 
detection and limit of quantitation [15]. 
Precision 
System precision 
Five replication injection of 1 µg/ml standard solutions showed 
percent RSD less than 2, which indicates the acceptable 
reproducibility and thereby the precision of the system [14, 16]. 
System precision results are tabulated in table 3. 
Method precision 
Method precision was determined by performing the analysis of the 
sample under the test of repeatability at working concentration. 
Seven injections of the sample from the same homogeneous mixture 
at working concentration showed %RSD less than 2 indicate that the 
developed method was precise by the test of repeatability [16, 17] 
and hence can be understood that the method gives consistently 
reproducible results in table 4. 
Linearity 
Linearity of aspirin, rosuvastatin, and clopidogrel was performed 
using a standard solution in the range of 1-7 μg/ml of each drug. The 
plots of peak area Vs respective concentration of aspirin, 
rosuvastatin, and clopidogrel were found to be linear in the range of 
1-7 µg/ml. The correlation coefficients were greater than 0.99 for 
each drug, which meets the method validation, acceptance criteria 
[16, 17] and hence the method is said to be linear (fig. 8-10). 
 
Table 3: Results of system precision 
Concentration Peak area (mV) 
Aspirin Rosuvastatin Clopidogrel 
1 μg/ml 208.800 42.651 187.546 
1 μg/ml 207.741 43.757 189.822 
1 μg/ml 205.800 42.651 187.546 
1 μg/ml 210.872 42.789 189.097 
1 μg/ml 206.197 43.483 185.229 
Mean 207.682 43.066 187.848 
SD 2 0.51 1.76 
% RSD 0.99 1.20 0.94 
# n: 5 i.e. number of injections, #SD: standard deviation, # % RSD: percentage relative standard deviation 
 
Table 4: Result of method precision 
Compounds  Intra-day Inter-day 
Concentration (µg/ml) n=7 % RSD Concentration (µg/ml) n=7 % RSD 
Aspirin 1-7 0.08 1-7 1.74 
Rosuvastatin 1-7 0.19 1-7 0.17 
Clopidogrel 1-7 0.11 1-7 0.09 
# % RSD: percentage relative standard deviation, #n: 7 i.e. number of injections 
 
Table 5: Data for linearity studies 
Compounds  Concentration range (µg/ml) Regression equation  R2 
Aspirin 1-7 y=258.7x+86.52 0.999 
Rosuvastatin 1-7 y=50.583x+9.5243 0.9989 
Clopidogrel 1-7 y=165.46x+37.867 0.9988 
#n: 7 i.e. number of injections, #R: Correlation coefficient. 
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Fig. 8: Linearity plot of aspirin 
 
 
Fig. 9: Linearity plot of rosuvastatin 
 
 
Fig. 10: Linearity plot of clopidogrel 
 
Accuracy and recovery 
Recovery studies were performed at three different levels 80, 100 
and 120 %. The sample was spiked with known amounts of aspirin, 
rosuvastatin and clopidogrel. The % RSD of accuracy study was 
found to be within specific limits, and thus we can conclude that the 
developed method is suitable for assay and there is no interference 
of excipients of the pharmaceutical dosage form. The recovery data 
from the study were reported in table 6-8. 
Robustness 
Deliberate variations were made in the method and % RSD was 
calculated plus and minus flow rate and mobile phase ratios were the 
variations that were analyzed. Small but deliberate variations were 
made in the method parameters, and it was found that % RSD values for 
all the variations were in acceptable limits. This indicated that the 
method is robust and it can be used within small variations of flow rate 
and mobile phase, without having a measurable effect on the result. 
 





% RSD % Recovery 
80 79.9±0.89 1.19 99.81 
100 101±1.09 1.07 100.09 
120 119±1.79 1.74 99.87 
# %RSD: percentage relative standard deviation 
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Table 7: Accuracy study of rosuvastatin 
Spiked concentration (µg/ml) Measured concentration (µg/ml) mean±SD % RSD % Recovery 
80 78.9±1.15 1.44 99.77 
100 102±0.89 0.88 100.15 
120 119±0.20 0.17 100.32 
# % RSD: percentage relative standard deviation, #SD: standard deviation 
 
Table 8: Accuracy study of clopidogrel 
Spiked concentration (µg/ml) Measured concentration (µg/ml) mean±SD % RSD % Recovery 
80 79.2±0.46  0.58 100.04 
100 99.7±0.25 0.30 99.47 
120 120±0.21 0.17 100.06 
# % RSD: percentage relative standard deviation, #SD: standard deviation 
 
Table 9: Result of Robustness of standard drugs 
Parameters Retention time (min) 
Flow rate Aspirin Rosuvastatin Clopidogrel 
0.8 3.98 6.54 16.17 
1.2 3.69 6.40 16.24 
mean±SD 3.83±0.20 6.47±0.09 16.2±0.04 
Mobile phase ratio (Organic: Aqueous)  Retention time (min) 
55:45 4.01 6.60 16.89 
53:47 3.90 6.48 16.75 
mean±SD 3.955±0.77 6.54±0.08 16.82±0.09 
# %RSD: percentage relative standard deviation, #SD: standard deviation 
 
Sensitivity  
The sensitivity of measurement of aspirin, rosuvastatin and 
clopidogrel by use of the proposed method was estimated in terms 
of the limit of quantitation (LOQ) and limit of detection (LOD). LOQ 
and LOD were calculated by the use of the equations LOD = 3.3σ/S 
and LOQ = 10σ/S where σ is the standard deviation of intercepts of 
calibration plots and S is the average of the slopes of the 
corresponding calibration plot (table 10). 
  
Table 10: LOD and LOQ for aspirin, rosuvastatin and clopidogrel 
Compounds  LOD (µg/ml) LOQ (µg/ml) 
Aspirin 0.005 0.01 
Rosuvastatin 0.01 0.05 
Clopidogrel 0.009 0.002 
#LOD: limit of detection, # LOQ: limit of quantitation. 
 
Forced degradation studies 
 
Table 11: Forced degradation study 
Types of degradation Peak area (mV) % of degradation % of degradation 
 Aspirin 
Acidic 36.469 14.54 
Base 520.681 26.97 
Neutral 34.024 10.2 
Oxidative 545.874 27.01 
Thermal  244.697 8.07 
Rosuvastatin 
 R1 R2  
Acidic 37.714 3.787 23.35 
Base 171.653 - 12.24 
Neutral 39.115 61.825 19.27 
Oxidative 3.834 4.228 4.35 
Photo 2.479 3.137 2.88 
Clopidogrel 
 C1 C2  
Acidic 6.990  4.58 
Base 19.507  9.78 
Neutral 2.794 3.772 17.21 
Oxidative 3.199  2.20 
Photo 8.102 1.274 8.70 
Thermal  3.298 5.124 8.71 
Acidic 6.990  4.58 
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The results obtained from the above set of observations prove that 
the method is useful in the qualitative and quantitative analysis of 
the standard drug with pharmaceutical dosage form. Moreover, 
various analytical methods for estimation of aspirin, rosuvastatin 
and clopidogrel alone were reported and in combination with other 
drugs. However, there is no HPLC and stability indicating assay 
method is reported for analysis and for simultaneous estimation of 
aspirin, rosuvastatin and clopidogrel combination and the novel 
method developed in this report is the first of its kind. The 
developed method is based on the use of a very economical solvent, 
had short chromatographic time and hence can be performed with 
ease. 
CONCLUSION 
The developed RP-HPLC method is simple, economical, specific, 
accurate and precise for the simultaneous estimation of aspirin, 
rosuvastatin, and clopidogrel in the combined capsule dosage form. 
The developed method offers good resolution between aspirin, 
rosuvastatin and clopidogrel. It was successfully validated in terms 
of system suitability, linearity, range, precision, accuracy, specificity, 
LOD, LOQ and robustness as per ICH guidelines. So, the described 
method is suitable for routine analysis and quality control of 
pharmaceutical preparations comprising these drugs either as an 
individual or in combination. Developed stability indicating 
analytical method can be used to check the stability of the 
compounds and was found suitable to determine % degradation of 
drugs in pharmaceutical dosage form. 
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